diffuse large b cell lymphoma
Conditions
Interventions
experimental group:anti-PD-1 monoclonal antibody and R-CHOP
Sponsors
Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Histopathologically confirmed with CD5+ diffuse large B cell lymphoma, previously untreated. 2. Age =18. 3. ECOG: 0-2 points. 4. Measurable lesions on CT scan: at least 1 lesion/lymph node with long axis > 1.5cm. 5. No prior chemotherapy, radiation or antibody therapy (surgery and glucocorticoid can be included). 6. Good organ function (creatinine =1.5mg/ dL, total bilirubin =2.0 mg/ dL, transaminase level less than twice the normal upper limit, left ventricular ejection fraction =50%). 7. No other serious underlying diseases.
Exclusion criteria
Exclusion criteria: 1. Patients with primary or secondary central nervous system lymphoma. 2. Patients receiving glucocorticoid therapy. 3. Patients who cannot aovid pregnancy during treatment. 4. Patients who cannot comply with the requirements of research treatment and monitoring. 5. Patients known to be allergic to any of the drugs in the treatment regimen. 6. Vulnerable groups: including critical patients, pregnant women, people with cognitive impairment, people with mental illness, juveniles, etc. 7. Other patients who were not eligible for inclusion by investigators evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| progression-free survival, overall survival, CNS relapse rate;Safety;The relationship between clinicopathologic, cytogenetic and molecular biological characteristics and treatment efficacy; | — |
Countries
China
Contacts
Public ContactJin Zhang
Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University
Outcome results
None listed